Astellas Pharma Inc. / Mitobridge, Inc.

Primary Mitochondrial Myopathies (PMM)

Disease Overview

Primary mitochondrial myopathies are inherited disorders in which mutations in mitochondrial or nuclear DNA impair the function of muscle-cell mitochondria, causing exercise intolerance, fatigue, muscle weakness, and atrophy. Patients have severely limited aerobic capacity and progressive functional decline; the diseases are heterogeneous, frequently misdiagnosed, and have no FDA-approved disease-modifying therapy. Management is supportive, focused on symptom relief and avoidance of triggers.

Competitive Landscape

The PMM space at deal close (January 2018) was almost entirely pre-commercial, with no FDA-approved disease-modifying therapy and only supportive care available (vitamin/cofactor cocktails, exercise, mitochondrial 'respiratory chain' supplements). The leading clinical-stage competitors were Stealth BioTherapeutics' elamipretide (a cardiolipin-binding tetrapeptide that later failed its primary PMM Phase 3 endpoint in 2019 and was rejected for Barth syndrome by FDA), Reata's omaveloxolone (an Nrf2 activator focused on Friedreich's ataxia rather than PMM proper), and academic gene therapy programs for specific mtDNA mutations. NORD and the United Mitochondrial Disease Foundation positioned PMM as a high-unmet-need orphan space. ASP0367 (bocidelpar sulfate), as a selective oral PPAR-delta modulator targeting mitochondrial biogenesis and fatty acid oxidation, offered a mechanistically differentiated approach. Astellas earned FDA Fast Track designation in 2020 and launched the MOUNTAINSIDE Phase 2/3 program. The deal positioned Astellas to compete directly with Stealth on the leading endpoint (6-minute walk test) in a category where elamipretide's regulatory setbacks created an opening for next-in-class oral candidates.